LBx-PA01

N/A

Report date: 2025/08/28 17:42:38

Base Information

Drug NameLBx-PA01
Drug Alias NameCRISPR/Cas3-based antimicrobial therapeutics (Locus Bioscience)
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas3
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPseudomonas aeruginosa pneumonia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLocus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsPseudomonas aeruginosa pneumonia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A